It’s still early days for artificial intelligence (AI) in the pharma and healthcare space. So much depends on navigating the regulatory environment, yet great strides are being made … they’re just not quite as sexy as, say, a chatbot or what IBM once promised Watson would be.
To learn more about what Intouch’s Justin Chase, EVP of innovation, and other pharma marketers see as the behind-the-scenes benefits of AI, check out this special feature from PharmaLive.
Why AI Equity Is the Next Step for Transformational Pharma
Artificial intelligence is here to stay, and it has the potential to improve health outcomes when done right. But is the data informing your AI biased? How can you know, and what can you do about it? Intouch’s VP of innovation, Abid Rahman, shares insights and advice.
Intouch & Athenex Oncology Talk AI at Frontiers Health Global Hybrid Conference
What’s the best approach for investments in AI-based implementations? At this year’s Frontiers Health conference, Intouch experts will discuss the ‘what’ and ‘how’; we’ll also hear a case study on creating an augmented-reality tool to help oncology HCPs empathize with patients undergoing chemotherapy, developed together with Athenex Oncology.